{"name": "Ziarco Pharma",
 "permalink": "ziarco-pharma",
 "crunchbase_url": "http://www.crunchbase.com/company/ziarco-pharma",
 "homepage_url": "http://www.ziarcopharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@ziarcopharma.com",
 "phone_number": "",
 "description": "Clinical stage biotechnology company ",
 "created_at": "Mon Nov 05 10:24:00 UTC 2012",
 "updated_at": "Wed Dec 12 07:33:00 UTC 2012",
 "overview": "\u003Cp\u003EZiarco is an independent, clinical stage biotechnology company progressing novel \u0026amp; differentiated therapies for inflammatory and allergic diseases, using both oral and topical routes of delivery. Ziarco has 4 major development programmes staffed by highly experienced drug development professionals.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       52],
      "assets/images/resized/0021/8782/218782v1-max-150x150.jpg"],
     [[250,
       88],
      "assets/images/resized/0021/8782/218782v1-max-250x250.jpg"],
     [[281,
       99],
      "assets/images/resized/0021/8782/218782v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$6M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.marketwatch.com/story/ziarco-founded-with-series-a-financing-to-develop-first-in-class-anti-inflammatory-and-anti-allergic-medicines-2012-11-05",
    "source_description": "Ziarco Founded with Series A Financing to Develop First-in Class Anti-inflammatory and Anti-allergic Medicines",
    "raised_amount": 6000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 11,
    "funded_day": 5,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Biotechnology Value Fund",
         "permalink": "biotechnology-value-fund",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pfizer Venture Investments",
         "permalink": "pfizer-venture-investments",
         "image":
          {"available_sizes":
            [[[150,
               97],
              "assets/images/resized/0025/2881/252881v1-max-150x150.png"],
             [[200,
               130],
              "assets/images/resized/0025/2881/252881v1-max-250x250.png"],
             [[200,
               130],
              "assets/images/resized/0025/2881/252881v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Lombard House",
    "address2": "12-17 Upper Bridge Street, Offices 205-6, Canterbury",
    "zip_code": "CT1 2NF",
    "city": "Kent",
    "state_code": null,
    "country_code": "GBR",
    "latitude": 51.2760599,
    "longitude": 1.0826563}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}